Tackling the Serious Global
Challenges in Infectious Disease

Appili was created to deliver innovative drug development programs for unmet patient needs across a broad spectrum of infectious diseases 

ACCELERATING drug development

Advancing DRUG DEVELOPMENT IN infectious disease AND BIODEFENSE to provide solutions to patients, doctors, and society

experienceD Leadership team

Leadership team skilled in advancing programs with upside potential

partnering with Appili

Active partnering and in-licensing efforts to expand clinical programs and accelerate commercialization

Innovation Across a Broad Spectrum of Anti-Infectives

LIKMEZ™ (ATI-1501)

A novel oral taste-masked suspension of metronidazole to treat serious anaerobic and protozoal infections

ATI-1701

A potential first-in-class live-attenuated vaccine for tularemia, a serious biothreat

ATI-1801

A novel topical antiparasitic product to treat disfiguring skin infections around the world